New Alzheimer's drug ABBV-1758 enters early human trials
NCT ID NCT07599670
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests an experimental drug called ABBV-1758 in about 210 people with Alzheimer's disease. The drug is given by IV or injection every 4 weeks for 24 weeks. Researchers are checking if it is safe and whether it can reduce amyloid plaques in the brain, a hallmark of Alzheimer's.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
ABBV-1758
What this could lead to
If it works, this could point toward a treatment that slows Alzheimer's by reducing amyloid buildup in the brain.
What could go wrong
This is an early Phase 1/2 trial with only 210 participants, so results may not confirm effectiveness. There are also known risks like brain swelling or bleeding (ARIA).
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ALZHEIMER S DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Adams Clinical /ID# 277754
RECRUITINGWatertown, Massachusetts, 02472, United States
-
Alpine Clinical Research Center - Boulder - 47th Street /ID# 277856
RECRUITINGBoulder, Colorado, 80301, United States
-
Alzheimer'S Research And Treatment Center - Stuart /ID# 278206
RECRUITINGStuart, Florida, 34997, United States
-
Alzheimer's Research And Treatment Center - Wellington /ID# 277749
RECRUITINGWellington, Florida, 33414, United States
Contact Phone: •••-•••-••••
-
Conquest Research - Winter Park /ID# 277760
RECRUITINGWinter Park, Florida, 32789, United States
Contact Phone: •••-•••-••••
-
Irvine Center for Clinical Research /ID# 277752
RECRUITINGIrvine, California, 92614, United States
-
K2 Medical Research - Clermont /ID# 277859
RECRUITINGClermont, Florida, 34711, United States
-
K2 Medical Research - The Villages /ID# 278290
RECRUITINGLady Lake, Florida, 32159, United States
-
Kerwin Medical Center /ID# 277788
RECRUITINGDallas, Texas, 75231, United States
Contact Phone: •••-•••-••••
-
Key Clinical Research LLC /ID# 277800
RECRUITINGBradenton, Florida, 34207, United States
Contact Phone: •••-•••-••••
-
Neurology Clinic - Cordova /ID# 277790
RECRUITINGCordova, Tennessee, 38018, United States